Literature DB >> 3312988

Is the clinical expression of primary hyperparathyroidism a function of the long-term vitamin D status of the patient?

C R Kleeman1, K Norris, J W Coburn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312988

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


× No keyword cloud information.
  6 in total

Review 1.  Cellular physiology and pathophysiology of the parathyroid glands.

Authors:  G Akerström; J Rastad; S Ljunghall; P Ridefelt; C Juhlin; E Gylfe
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

2.  Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology.

Authors:  Gaurav Agarwal; Kaushal K Prasad; Dilip K Kar; Narendra Krishnani; Rakesh Pandey; Saroj K Mishra
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis.

Authors:  R S Weinstein; R L Harris
Journal:  Calcif Tissue Int       Date:  1990-06       Impact factor: 4.333

4.  The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region.

Authors:  H Raef; S Ingemansson; S Sobhi; A Sultan; M Ahmed; M Chaudhry
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

5.  The cause of maintained hypercalciuria after the surgical cure of primary hyperparathyroidism is a defect in renal calcium reabsorption.

Authors:  M L Farias; A G Delgado; D Rosenthal; J G Vieira; T Kasamatsu; M J Lazarevitch; M F Pereira; M B Lima
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

6.  Surgery for sporadic primary hyperparathyroidism in the elderly.

Authors:  U Ohrvall; G Akerström; S Ljunghall; E Lundgren; C Juhlin; J Rastad
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.